izusek/E+ via Getty Images
- Bayer (OTCPK:BAYRY) said that two phase 3 studies showed its hot flashes drug elinzanetant significantly reduced the frequency and severity of moderate to severe vasomotor symptoms associated with menopause compared to placebo.
- The drug also showed improvements in sleep disturbances and menopause related quality of life compared to placebo, secondary endpoints.
- In OASIS 1, one of the two trials, elinzanetant demonstrated mean reduction versus placebo in terms of frequency at week 4 of -3.29 and -3.22 at week 12. For severity, the figures at weeks 4 and 12 were, respectively, -0.33 and -0.40.
- Elinzanetant is a dual neurokinin-1,3 (NK-1,3) receptor antagonist with once-daily dosing.
- Bayer will present the data at the upcoming 2024 American College of Obstetricians and Gynecologists (ACOG) Annual Clinical & Scientific Meeting.
from Business – My Blog https://ift.tt/i2rDVfv
via IFTTT
.jpg)
0 Comments